Press release
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2025 on Thursday, February 12, 2026, before the U.S. financial markets open.\n\n\nManagement will provide an update on the Company and discuss fourth quarter and year-end 2025 results as well as expectations for the future via conference call on Thursday, February 12, 2026 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.\n\n\nAbout Alnylam Pharmaceuticals\n\n\nAlnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit www.alnylam.com or follow Alnylam on X, LinkedIn, Facebook, Instagram, or YouTube.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20260129185762/en/\n\nAlnylam Pharmaceuticals, Inc.\nChristine Akinc\n(Investors and Media)\n617-682-4340\n\n\nJosh Brodsky\n(Investors)\n617-551-8276\n\n\nSource: Alnylam Pharmaceuticals, Inc.","length":5466,"tagName":"div"}]